tetano
Editor, Senior Moderator
Pediatr Infect Dis J
. 2022 Dec 29.
doi: 10.1097/INF.0000000000003814. Online ahead of print.
Remdesivir Use in Pediatric Patients for SARS-CoV-2 Treatment: Single Academic Center Study
Allison M Samuel[SUP] 1 [/SUP], Larissa L Hacker[SUP] 1 [/SUP], Jessica Zebracki[SUP] 1 [/SUP], Monica C Bogenschutz[SUP] 1 [/SUP], Lucas Schulz[SUP] 1 [/SUP], Jill Strayer[SUP] 1 [/SUP], Joshua P Vanderloo[SUP] 1 [/SUP], Pelin Cengiz[SUP] 2 [/SUP], Sheryl Henderson[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Millions of children in the United States have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with many infections leading to hospitalization. For pediatric patients, especially younger children, treatment options are limited. Remdesivir has demonstrated a positive safety and efficacy profile in adults, but little data is published regarding remdesivir use in pediatric patients. Additional data for SARS-CoV-2 treatments in pediatric patients is required to prevent further SARS-CoV-2-related morbidity and mortality. At a single pediatric academic medical center, the safety and efficacy of remdesivir was evaluated.
Methods: A retrospective review of patients admitted to a pediatric academic medical center who received remdesivir over a 17-month period was completed. All pediatric patients who received at least 1 dose of remdesivir were included. Safety and efficacy were assessed using national organization's definitions of clinical improvement, bradycardia, hypertension, acute kidney injury and drug-induced liver injury.
Results: There were 48 pediatric patients included in this study with 29% of patients admitted to the pediatric intensive care unit. Less than one-third of patients received the full treatment course of remdesivir, with over half of patients not completing therapy due to symptomatic improvement or hospital discharge. Majority of patients required some level of supplemental oxygen support. The median World Health Organization score was consistent throughout all 5 days of therapy. No patients experienced significant bradycardia, hypertension, acute kidney injury, or drug-induced liver injury.
Conclusions: Remdesivir may correlate with clinical stability or improvement and demonstrates safety when used in pediatric patients. A randomized controlled trial is needed to confirm these findings.
. 2022 Dec 29.
doi: 10.1097/INF.0000000000003814. Online ahead of print.
Remdesivir Use in Pediatric Patients for SARS-CoV-2 Treatment: Single Academic Center Study
Allison M Samuel[SUP] 1 [/SUP], Larissa L Hacker[SUP] 1 [/SUP], Jessica Zebracki[SUP] 1 [/SUP], Monica C Bogenschutz[SUP] 1 [/SUP], Lucas Schulz[SUP] 1 [/SUP], Jill Strayer[SUP] 1 [/SUP], Joshua P Vanderloo[SUP] 1 [/SUP], Pelin Cengiz[SUP] 2 [/SUP], Sheryl Henderson[SUP] 3 [/SUP]
Affiliations
- PMID: 36728726
- DOI: 10.1097/INF.0000000000003814
Abstract
Background: Millions of children in the United States have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with many infections leading to hospitalization. For pediatric patients, especially younger children, treatment options are limited. Remdesivir has demonstrated a positive safety and efficacy profile in adults, but little data is published regarding remdesivir use in pediatric patients. Additional data for SARS-CoV-2 treatments in pediatric patients is required to prevent further SARS-CoV-2-related morbidity and mortality. At a single pediatric academic medical center, the safety and efficacy of remdesivir was evaluated.
Methods: A retrospective review of patients admitted to a pediatric academic medical center who received remdesivir over a 17-month period was completed. All pediatric patients who received at least 1 dose of remdesivir were included. Safety and efficacy were assessed using national organization's definitions of clinical improvement, bradycardia, hypertension, acute kidney injury and drug-induced liver injury.
Results: There were 48 pediatric patients included in this study with 29% of patients admitted to the pediatric intensive care unit. Less than one-third of patients received the full treatment course of remdesivir, with over half of patients not completing therapy due to symptomatic improvement or hospital discharge. Majority of patients required some level of supplemental oxygen support. The median World Health Organization score was consistent throughout all 5 days of therapy. No patients experienced significant bradycardia, hypertension, acute kidney injury, or drug-induced liver injury.
Conclusions: Remdesivir may correlate with clinical stability or improvement and demonstrates safety when used in pediatric patients. A randomized controlled trial is needed to confirm these findings.